InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,951.34
(
0.26%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ash111

Send PM Follow Ignore
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

ash111

Re: None

Thursday, 09/22/2016 2:05:44 PM

Thursday, September 22, 2016 2:05:44 PM

Post# of 97237
KTOV looking great.ACST loading up for the long term too.GSK is a $105B Co. Results from a randomized, open-label, four-way, crossover study in 56 healthy volunteers showed a comparable safety profile between CaPre and GlaxoSmithKline's (GSK) LOVAZA (omega-3-acid ethyl esters) capsules. In fasting subjects, CaPre showed better bioavailability than LOVAZA as measured by EPA and DHA levels.

ACST a perfect buyout potential imo. 10.7m O/S (cap is really a joke,only $20m)
http://seekingalpha.com/news/3208711-acasti-pharma-advances-high-triglyceride-fighter-capre-bridging-study-shows-similar-safety

investors took profits past days after great results(past week) but forgot,cap is still laughable.

ATEC passed 8...as said, solid companies always paying off.

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up